<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increasing evidence indicates that a progressive decrease in the functional beta-cell mass is the hallmark of both type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The underlying causes, beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and impaired secretory function, seem to be partly mediated by macrophage production of interleukin (IL)-1beta and/or high-<z:chebi fb="105" ids="17234">glucose</z:chebi>-induced beta-cell production of IL-1beta </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment of type 1 and type 2 diabetic patients with the <z:chebi fb="120" ids="26216">potassium</z:chebi> channel opener <z:chebi fb="0" ids="4495">diazoxide</z:chebi> partially restores insulin secretion </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we studied the effect of <z:chebi fb="0" ids="4495">diazoxide</z:chebi> and of the novel <z:chebi fb="120" ids="26216">potassium</z:chebi> channel opener NN414, selective for the beta-cell <z:chebi fb="120" ids="26216">potassium</z:chebi> channel SUR1/Kir6.2, on <z:chebi fb="105" ids="17234">glucose</z:chebi>- and IL-1beta-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and impaired function in human beta-cells </plain></SENT>
<SENT sid="4" pm="."><plain>Exposure of human islets for 4 days to 11.1 and 33.3 mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi>, 2 ng/ml IL-1beta, or 10 and 100 micromol/l of the <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> <z:chebi fb="0" ids="27999">tolbutamide</z:chebi> induced beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and impaired <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion </plain></SENT>
<SENT sid="5" pm="."><plain>The deleterious effects of <z:chebi fb="105" ids="17234">glucose</z:chebi> and IL-1beta were blocked by 200 micromol/l <z:chebi fb="0" ids="4495">diazoxide</z:chebi> as well as by 3 and 30 micromol/l NN414 </plain></SENT>
<SENT sid="6" pm="."><plain>By Western blotting with phosphospecific antibodies, <z:chebi fb="105" ids="17234">glucose</z:chebi> and IL-1beta were shown to activate the extracellular signal-regulated kinase (ERK) 1/2, an effect that was abrogated by 3 micromol/l NN414 </plain></SENT>
<SENT sid="7" pm="."><plain>Similarly, 1 micromol/l of the <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase/ERK kinase 1/2 inhibitor PD098059 or 1 micromol/l of the l-type Ca(2+) channel blocker nimodipine prevented <z:chebi fb="105" ids="17234">glucose</z:chebi>- and IL-1beta-induced ERK activation, beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and impaired function </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, islet release of IL-1beta in response to high <z:chebi fb="105" ids="17234">glucose</z:chebi> could be abrogated by nimodipine, NN414, or PD098059 </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, in human islets, <z:chebi fb="105" ids="17234">glucose</z:chebi>- and IL-1beta-induced beta-cell secretory dysfunction and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> are Ca(2+) influx and ERK dependent and can be prevented by the beta-cell selective <z:chebi fb="120" ids="26216">potassium</z:chebi> channel opener NN414 </plain></SENT>
</text></document>